METHOD OF PREDICTING PROGRESSION OF HIV INFECTION IN PATIENTS RECEIVING ANTIRETROVIRAL THERAPY Russian patent published in 2019 - IPC G01N33/53 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely immunology, and enables predicting the progression of HIV infection in the patients receiving the antiretroviral therapy. That is ensured by determining a complex of immunological indices by a solid-phase enzyme immunoassay. Concentration of lipopolysaccharide-binding protein (LBP), the level of key pro-inflammatory cytokines: INF-γ, INF-α, IL-6. Using flow cytometry, percentage of activated cells with phenotype: CD3+/CD8+/CD38+/HLA-DR. Critical values of the levels of the above indicators are assigned points: increasing the level of LBP from 55.1 to 80.0 mcg/ml corresponds to 1 point; from 80.1 mcg/ml and higher – 2 points. Increase of INF-γ from 15.1 to 40.0 pg/ml corresponds to 1 point; from 40.1 pg/ml and higher – 2 points. Increase of INF-α from 9.1 to 15.0 pg/ml corresponds to 1 point; from 15.1 pg/ml and higher – 2 points. Increase in IL-6 concentration in excess of 10.1 pg/ml is estimated as 1 point. Percentage of CD3+/CD8+/CD38+/HLA-DR exceeds 22.4 % corresponds to 1 point. That is followed by calculating the total inflammatory coefficient Kv equal to the sum of each index. If Kv is equal to 1 to 3 points, a low risk of progressing HIV infection is determined. If Kv is 4 or more, a high risk of progressing HIV infection is predicted.

EFFECT: invention provides more accurate prediction of the progression of HIV infection on the basis of assessing the probability of developing a systemic inflammation in the patient, which reduces the immunological effectiveness of the antiretroviral therapy.

1 cl, 9 dwg, 6 tbl, 3 ex